How can clonoSEQ be used to inform patient management decisions?
Learn how clonoSEQ MRD results may inform clinician decision-making. Explore the Real-world Experience Hub, a new repository of clinician and patient perspectives on the practical value of MRD, published real-world evidence and data illustrating how clonoSEQ is really being used.

Answers that enhance clinical insight
Clear results with robust supporting data
Clinicians receive clonoSEQ® test results via an informative clinical report. These visually engaging reports provide clinicians with a clear MRD test result while also incorporating rich, quantitative data and comprehensive analysis for clinicians who want to dig deeper.
Results delivered via secure online portal
All reports are delivered via a secure web portal, which provides convenient access to patient results when needed.
Log in to access your patient’s clonoSEQ test results.
LOG INTO PORTALReport content customized, which may inform decision making
Explore example clonoSEQ reports:
The Clonality (ID) Test is used to identify dominant DNA sequences in a high disease load diagnostic sample.
Identification of at least one dominant DNA sequence is a prerequisite to future monitoring of MRD. After the dominant DNA sequences has been identified utilizing the Clonality (ID) Test, subsequent monitoring of the associated clone(s) can be completed by ordering Tracking (MRD) Tests.
The clonoSEQ B-cell Tracking (MRD) Report provides results based on analysis of the IgH, IgK and IgL loci as well as Bcl1 and Bcl2 translocations.
After the dominant DNA sequences has been identified utilizing the Clonality (ID) Test, subsequent monitoring of the associated clone(s) can be completed by ordering Tracking (MRD) Tests throughout treatment.
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Explore clonoSEQ clinical reports in more depth
Questions about clonoSEQ reports?
Adaptive’s Clinical Services and Clinical Consultant teams provide clinicians with support throughout the clonoSEQ testing process and offer unmatched expertise in the field of residual disease assessment.[2-4] Their goal is to provide a seamless user experience, empowering clinicians with timely results that can inform their treatment decisions.
Contact Us
Make an inquiry to learn more about our products.
Citations
- clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020. https://clonoseq.com/technical-summary.
- 42 CFR § 493.1417
- MD, DO, or DPM with a current medical license
- Doctoral degree in chemical, physical, biological or clinical laboratory sciences with certification by a board approved by HHS.